Swep Bio, Inc. — SEC Form D Filing
Swep Bio, Inc. filed an SEC Form D on October 29, 2026, reporting $2.50M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 29, 2026
- Amount reported
- $2.50M
- Round stage
- Seed stage, as Swep Bio has raised $2.5 million of an initial equity offering to support early R&D and foundational operations.
- Industry
- Biotechnology
- Website
- https://www.swepbio.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Traditional therapeutic pipelines struggle to rapidly identify and validate novel biological targets for complex diseases.
Solution
Swep Bio develops targeted biopharmaceutical therapeutics to treat critical unmet medical conditions.
Why now
Recent advancements in molecular biology and high-throughput screening allow early-stage biotech companies to rapidly translate biological insights into therapeutic candidates.
Source: SEC EDGAR Form D filing